AstraZeneca Launches Live Click-to-Chat Feature on CRESTOR and NEXIUM Consumer Websites

Technology provides greater accessibility and convenience to patients, caregivers

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) announced today the launch of “click-to-chat” on CRESTOR.com and PurplePill.com. The new “click-to-chat” technology gives consumers an option to contact a live AstraZeneca customer service representative with just a click of a button. Click-to-chat is a live, online chat option, similar to instant messaging, and can be accessed at the “Contact Us” page of the CRESTOR® (rosuvastatin calcium) and NEXIUM® (esomeprazole magnesium) websites.

“AstraZeneca understands that our consumers want flexibility, especially when it comes to health information,” said Donna Holder, senior director, AstraZeneca Information Center. “This new resource enables consumers to have easier access to the information they seek through the convenience of a real-time, online channel.”

Patients can contact the AstraZeneca Information Center by telephone at 1-800-236-9933, Monday through Friday from 8 a.m. to 6 p.m. ET, excluding holidays, or by submitting an e-mail request form. In addition, CRESTOR and NEXIUM brand websites launched “Call Me Now” in October 2010. Call Me Now offers visitors the option to receive a personal phone call from an Information Center representative to help answer their questions about CRESTOR or NEXIUM without having to go through telephone prompts, wait on the line or listen to a recorded operator.

“AstraZeneca is one of the first pharmaceutical companies to use this technology, making it a very forward-thinking company in the pharmaceutical industry,” said Don Keane, vice president of marketing and product strategy for Angel, a leading provider of customer interaction solutions such as Interactive Voice Response (IVR) and chat technologies. “Click-to-chat enables consumers to engage in a live-chat session and interact directly with AstraZeneca representatives, adding another communications channel for great customer service.”

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

CRESTOR is a registered trademark of the AstraZeneca group of companies.

NEXIUM and the color purple as applied to the capsule are registered trademarks and Purple Plus and THE PURPLE PILL are trademarks of the AstraZeneca group of companies.

1146300 3/11



CONTACT:

AstraZeneca
Media Inquiries:
Rachelle Benson, +1-302-885-5853

KEYWORDS:   United States  North America  Delaware

INDUSTRY KEYWORDS:   Seniors  Women  Technology  Internet  Health  Pharmaceutical  Communications  Marketing  Other Communications  Consumer  Family  General Health  Men

MEDIA:

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.